Cargando…

TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) changed the standard care of patients with lung squamous cell carcinoma (LUSC). It is an urgent need to precisely predict the population’s response to ICIs. The aim of the study was to explore novel biomarkers for LUSC immunotherapy and the potenti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Jiangyong, Fan, Zaiwen, Zhou, Zhipeng, Zhang, Ping, Bai, Jing, Li, Xu, Tang, Min, Fan, Nannan, Wu, Xiaonan, Nie, Xin, Chen, Xiaoyan, Ma, Di, Chen, Xi, Cui, Liang, Xia, Xuefeng, Yang, Ling, Yi, Xin, Li, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320428/ https://www.ncbi.nlm.nih.gov/pubmed/35884443 http://dx.doi.org/10.3390/cancers14143382

Ejemplares similares

NF-YA Overexpression in Lung Cancer: LUSC
por: Bezzecchi, Eugenia, et al.
Publicado: (2019)

LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma
por: Wang, Longrong, et al.
Publicado: (2021)

Multi‐omics data identified TP53 and LRP1B as key regulatory gene related to immune phenotypes via EPCAM in HCC
por: Shi, Liang, et al.
Publicado: (2022)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer
por: Wieser, Verena, et al.
Publicado: (2018)

Network pharmacology and bioinformatics analysis identifies potential therapeutic targets of Naringenin against COVID-19/LUSC
por: Wu, Wen-yu, et al.
Publicado: (2023)

Characteristics and prognosis of rrDLBCL with TP53 mutations and a high‐risk subgroup represented by the co‐mutations of DDX3X‐TP53
por: Gao, Fan, et al.
Publicado: (2023)

Expression of wild-type and mutated TP53 in breast carcinomas
por: Baumbusch, LO, et al.
Publicado: (2005)

CRISPR screens are feasible in TP53 wild‐type cells
por: Brown, Kevin R, et al.
Publicado: (2019)

Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma()
por: Quaas, Alexander, et al.
Publicado: (2018)

Regulation of IFN-γ-mediated PD-L1 expression by MYC in colorectal cancer with wild-type KRAS and TP53 and its clinical implications
por: Guo, Libin, et al.
Publicado: (2022)

Differentiated regulation of immune-response related genes between LUAD and LUSC subtypes of lung cancers
por: Chen, Mengzhu, et al.
Publicado: (2016)

Reply to “CRISPR screens are feasible in TP53 wild‐type cells”
por: Haapaniemi, Emma, et al.
Publicado: (2019)

Redox-sensitive TP53INP1 SUMOylation as an oxidative stress sensor to activate TP53
por: Bonacci, Thomas, et al.
Publicado: (2014)

TP53 mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomas
por: Alos, Llucia, et al.
Publicado: (2020)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Synthetic lethality between TP53 and ENDOD1
por: Tang, Zizhi, et al.
Publicado: (2022)

TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma
por: Yu, Jiongjie, et al.
Publicado: (2023)

Correlation between serum IL-1β and miR-144-3p as well as their prognostic values in LUAD and LUSC patients
por: Wu, Chen, et al.
Publicado: (2016)

The antihypertensive felodipine shows synergistic activity with immune checkpoint blockade and inhibits tumor growth via NFAT1 in LUSC
por: Liang, Si-Yu, et al.
Publicado: (2023)

Maspin subcellular expression in wild-type and mutant TP53 gastric cancers
por: Gurzu, Simona, et al.
Publicado: (2020)

Wild-Type TP53 Predicts Poor Prognosis in Patients with Gastric Cancer
por: Deng, Wenhong, et al.
Publicado: (2021)

Cytological Immunostaining of HMGA2, LRP1B, and TP63 as Potential Biomarkers for Triaging Human Papillomavirus-Positive Women()
por: Jiang, Yunhui, et al.
Publicado: (2019)

Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia
por: Kogan, Aksinija A., et al.
Publicado: (2022)

Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD‐L1 immunotherapy
por: Wu, Chih‐Hsun, et al.
Publicado: (2019)

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation
por: Na, Bing, et al.
Publicado: (2019)

Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer
por: Albitar, Maher, et al.
Publicado: (2018)

The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC
por: Fu, Linhai, et al.
Publicado: (2020)

Dissecting the Immunological Profiles in NSD3-Amplified LUSC through Integrative Multi-Scale Analyses
por: Xu, Duo, et al.
Publicado: (2022)

Construction and validation of a cuproptosis-related lncRNA signature for the prediction of the prognosis of LUAD and LUSC
por: Wang, Yu, et al.
Publicado: (2023)

The impact of chemotherapeutic drugs on the CYP1A1-catalysed metabolism of the environmental carcinogen benzo[a]pyrene: Effects in human colorectal HCT116 TP53(+/+), TP53(+/−) and TP53(−/−) cells
por: Willis, Alexandra J., et al.
Publicado: (2018)

Self-restricted circular RNA circSOX2 suppressed the malignant progression in SOX2-amplified LUSC
por: Liang, Yingkuan, et al.
Publicado: (2022)

Haploinsufficiency Interactions of RALBP1 and TP53 in Carcinogenesis
por: Awasthi, Sanjay
Publicado: (2021)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

MDM4 Overexpressed in Acute Myeloid Leukemia Patients with Complex Karyotype and Wild-Type TP53
por: Li, Li, et al.
Publicado: (2014)

Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer
por: Ignacio, Rosa Mistica C., et al.
Publicado: (2018)

Identification of the key genes and characterizations of Tumor Immune Microenvironment in Lung Adenocarcinoma (LUAD) and Lung Squamous Cell Carcinoma (LUSC)
por: Zhang, Lemeng, et al.
Publicado: (2020)

S127: DELTATP73 IMPOSES TP53 MUTANT-LIKE PHENOTYPES INCLUDING DRUG RESISTANCE AND POOR PROGNOSIS ON TP53-WILD TYPE ACUTE MYELOID LEUKEMIA.
por: Pereira-Martins, Diego A, et al.
Publicado: (2023)

Efficacy and safety of anti‐PD‐1/PD‐L1 in combination with chemotherapy or not as first‐line treatment for advanced non‐small cell lung cancer: A systematic review and network meta‐analysis
por: Wang, Liming, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nks6nnmoj3f5phtoa15qnub9v6